3rd Quarter - Termination

WYETH for WYETH

Firm
Client
Income
—
Expenses
$681,738
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Sep 30, 2009

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Monitor U.S. trade policies relating to intellectual property protection under the WTO/TRIPS agreement health care reform legislation

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Natl Security Council (NSC); SENATE; Food & Drug Administration (FDA); Treasury, Dept of; U.S. Trade Representative (USTR); Executive Office of the President (EOP); Justice, Dept of (DOJ); HOUSE OF REPRESENTATIVES; White House Office; Natl Security Agency (NSA)

Trade (domestic/foreign) TRD

Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement Importation of FDA-approved pharmaceuticals

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; Justice, Dept of (DOJ); Food & Drug Administration (FDA); White House Office; SENATE; Executive Office of the President (EOP); State, Dept of (DOS); Natl Security Agency (NSA); Natl Security Council (NSC)

Taxation/Internal Revenue Code TAX

Taxation of International Operations of U.S. corporations generally; R&D tax credit; repatriation of foreign source income; deferral of U.S. taxation of foreign source income; taxation of employer provided healthcare.

LobbyistCovered position, as disclosed
LEO C JARDOT —
JULIE RABINOWITZ —

Contacted: White House Office; Natl Security Agency (NSA); Natl Security Council (NSC); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Food & Drug Administration (FDA); Justice, Dept of (DOJ); U.S. Trade Representative (USTR); Executive Office of the President (EOP); SENATE; Health & Human Services, Dept of (HHS); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; Childhood immunizations Dietary supplement issues Alzheimer's care Pediatric Studies and Trials Drug Safety/Clinical Trials Health care reform legislation FDA Pre-emption Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Chronic care out of pocket costs Vaccine Program H.R. 1427 - Access to Life-Saving Medicine Act H.R. 1548 - The Pathway for Biosimilars Act Legislative and regulatory issues related to hormone replacement therapies International public health issues International vaccine issues H.R. 1/S350 - The American Recovery and Reinvestment Act of 2009 H.R. 579 - The Food and Drug Administration Globalization Act S. 525/H.R. 1298 - The Pharmaceutical Market Access and Drug Safety Act of 2009 S. 301 - Physican Payments Sunshine Act of 2009 H.R. 573 - Authorized Generics S. 501 - Fair Prescription Drug Competition Act S. 369 - Preserve Access to Affordable Generics Act H.R. 1706 - Protecting consumer Access to Generic Drugs Act S.357 - Sunshine in Litigation Act of 2009 H.R. 3200 - American's Affordable Health Choices Act of 2009 S.1679 Affordable Health Choices Act S.1213 - Patient Centered Outcomes Research Act of 2009

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); State, Dept of (DOS); Executive Office of the President (EOP); White House Office; Health & Human Services, Dept of (HHS); Natl Security Agency (NSA); Treasury, Dept of; Natl Security Council (NSC); Justice, Dept of (DOJ)

Bills named: S. 1213 (111th), H.R. 3200 (111th), H.R. 1548 (111th), S. 357 (111th), H.R. 1427 (111th), H.R. 1706 (111th), H.R. 1298 (111th), S. 369 (111th), H.R. 579 (111th), S. 501 (111th), S. 301 (111th), H.R. 573 (111th), S. 1679 (111th), S. 525 (111th), H.R. 1 (111th)

Medicare/Medicaid MMM

Vaccines Medicare chronic disease coverage Implementation Issues concerning P.L. 108-173 - the Medicare Prescription Drug, Improvement and Modernization Act of 2003 Medicare coverage of pharmaceuticals, Medicare Part D Chronic care out of pocket costs Medicare Prescription Drug Benefit Medicaid drug rebate Medicare and Medicaid Drug Reimbursement Medicaid Part D Non-Interference S.301/HR 3138 Physician Payments Sunshine Act of 2009 S.547/H.R. 904 - Drug Rebate Equalization Act of 2009 H.R. 1725 - Voluntary State Discount Prescription Drug Plan Act of 2009 S.330/H.R. 684 - Medicare Prescription Drug Savings and Choice Act of 2009 S.266 - Medicare Prescription Drug Gap Reduction Act of 2009 S.1679 Affordable Health Choices Act

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Executive Office of the President (EOP); Food & Drug Administration (FDA); White House Office; Natl Security Agency (NSA); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Natl Security Council (NSC); Treasury, Dept of; Justice, Dept of (DOJ); State, Dept of (DOS)

Bills named: H.R. 904 (111th), S. 547 (111th), H.R. 1725 (111th), H.R. 3138 (111th), S. 330 (111th), H.R. 684 (111th), S. 266 (111th), S. 301 (111th), S. 1679 (111th)

Consumer Issues/Safety/Products CSP

FDA reform proposals; Pseudoephedrine H.R. 1259 DXM Distribution Act Monograph System Reform Proposal Pseudoephedrine Electronic Log Proposal S.1383 Dextromethorphan Abuse Reduction Act of 2009 H.R. 2749 Food Safety Enhancement Act of 2009 S. 510 Food Safety Modernization Act of 2009

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); SENATE; Justice, Dept of (DOJ); U.S. Trade Representative (USTR); Natl Security Council (NSC); White House Office; Natl Security Agency (NSA); Treasury, Dept of

Bills named: H.R. 1259 (111th), S. 510 (111th), H.R. 2749 (111th), S. 1383 (111th)

Pharmacy PHA

S. 726/H.R. 1427 - Access to Life-Saving Medicine Act, Follow-on Biologics H.R. 1548 - The Pathway for Biosimilars Act Biosimilars Drug Safety Prescription Drug Importation Import Safety Compounding H.R. 759 - Food and Drug Administration Globaliation Act of 2009 S. 510 - FDA Food Safety Modernization Act

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Health & Human Services, Dept of (HHS); Natl Security Agency (NSA); Food & Drug Administration (FDA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Justice, Dept of (DOJ); White House Office; SENATE; Natl Security Council (NSC)

Bills named: S. 510 (111th), H.R. 1548 (111th), S. 726 (111th), H.R. 1427 (111th), H.R. 759 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.